Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, ...

HEPZATO launch shows strong revenue growth, profitability, and U.S. expansion, marking a biotech turning point. Read why DCTH ...

The researchers described the unprecedented speed of the oversight steps as being "through alternative procedures." In month ...

In both children and adults, the drug allows for decreasing glucocorticoid dosing to physiological levels while still ...

Close collaboration between researchers and clinicians at Mayo is what makes the steps of translation — from discovery to the ...

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed ...

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative ...

Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First ...

Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase ...

Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...